Champions Oncology, trading under the ticker CSBR on NASDAQ, is starting to catch the eye of retail investors, but not without some skepticism. The stock's recent momentum, with a daily change rate of 1.06, suggests a mild uptick in interest. However, the valuation hype value of 4.59 compared to its real value of 5.43 indicates that the stock might be overvalued at current levels. Analysts have set a target price range between 7.96 and 9.71, with a consensus leaning towards a strong buy, yet the naive expected forecast value sits at a modest 4.45. This discrepancy raises questions about whether the enthusiasm is justified or if it's merely speculative. With a fiscal year ending in April, investors should keep an eye on upcoming financial reports, especially considering the company's last reported loss of 1.3K. While the potential upside price of 8.96 is enticing, the possible downside price of 0.0488 serves as a cautionary note for those considering jumping on the bandwagon. We primarily examine the price trends of Champions Oncology (NASDAQ: CSBR) and how they relate to various microeconomic factors. By using predictive analytics, we create daily price indicators for Champions Oncology and assess them alongside relevant influences. This analysis aims to provide a comprehensive overview of Champions Oncology, exploring its potential to become a consistent performer by January.
Champions Oncology (NASDAQ: CSBR) is drawing attention from retail investors, with its recent price percent change of 5.86% signaling potential momentum in the biotechnology sector. Despite a maximum drawdown of 22.49, the stock's current price of 4.88 suggests that investors are intrigued by its potential upside of 6.56, indicating a growing interest in its future prospects.
Key Points
Champions Oncology currently holds a "Strong Buy" rating from one analyst. To enhance this expert consensus, we offer trading advice based on our advanced recommendation engine. This tool employs a sophisticated algorithm that evaluates the company's growth potential by examining all available technical and fundamental data.Champions Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Champions Oncology
financial leverage refers to using borrowed capital as a funding source to finance Champions Oncology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Champions Oncology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Champions Oncology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Champions Oncology's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Champions Oncology's total debt and its cash.
The latest price spike of Champions Oncology could raise concerns from retail investors as the firm is trading at a share price of
4.88 on
18,443 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
January. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.51. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Champions Oncology partners.
| 2021 | 2022 | 2023 | 2024 (projected) |
Short Long Term Debt Total | 9.5M | 8.6M | 7.4M | 7.8M | Total Assets | 35.4M | 34.3M | 26.1M | 27.4M |
Current Deferred Revenue Breakdown
Champions Oncology Current Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Current Deferred Revenue is likely to grow to about 12.7
M this year. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At this time, Champions Oncology's Current Deferred Revenue is relatively stable compared to the past year.
| 2017 | 4.7 Million |
| 2018 | 4.02 Million |
| 2019 | 5.82 Million |
| 2020 | 6.26 Million |
| 2021 | 11.07 Million |
| 2022 | 12.78 Million |
| 2023 | 12.09 Million |
| 2024 | 12.7 Million |
They say, "The trend is your friend," and Champions Oncology (NASDAQ: CSBR) might just be riding a wave of retail investor interest. Despite a challenging financial landscape, with a debt-to-equity ratio of 1.03% and a return on equity at a loss of 4.32%, the company is garnering attention. With 49% of its shares owned by institutions, there's a notable foundation of institutional support, yet the stock's high price-to-earnings ratio of 220.00X suggests a premium valuation that might be driven by future growth expectations. Retail investors are likely intrigued by the potential upside, but the probability of bankruptcy at 41.59% is a reminder of the inherent risks in the biotechnology sector. As retail investors weigh these factors, the allure of Champions Oncology lies in its potential to capitalize on innovation within life sciences tools and services.
Our take on today Champions Oncology spike
Champions Oncology saw a significant jump today, but with the potential upside now capped at 6.56, it seems the stock's recent momentum might be waning. This could mean reduced volatility as the market settles around this new price. Investors should monitor the stock's behavior in the coming days, as this change might indicate a consolidation phase or a possible pullback. While the excitement of the surge is understandable, it's important to stay cautious and consider the broader market context before making any trading moves. Champions Oncology exhibits above-average downside volatility for the chosen time frame.
Understanding market volatility trends can help investors time their trades. Using volatility indicators effectively allows traders to assess the stock's risk against market fluctuations in both rising and falling markets.Despite today's modest market decline, Champions Oncology's robust performance suggests a compelling opportunity for investors. With an Analyst Overall Consensus rating of "Strong Buy" and a potential upside price reaching up to 8.96, the stock demonstrates significant promise. The highest estimated target price by analysts stands at 9.71, indicating confidence in its future growth. As the company continues to innovate and expand its oncology solutions, its valuation market value of 4.88 seems to provide a solid foundation for potential investors. While no investment is without risk, Champions Oncology's current trajectory and expert endorsements suggest it could be a rewarding addition to a diversified portfolio..
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Champions Oncology. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com